<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02123368</url>
  </required_header>
  <id_info>
    <org_study_id>CMM/ART</org_study_id>
    <secondary_id>2009-017624-72</secondary_id>
    <nct_id>NCT02123368</nct_id>
  </id_info>
  <brief_title>Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells</brief_title>
  <official_title>Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological)
      of intra-articular administration of autologous mesenchymal stem cells (MSCs) in patients
      with knee osteoarthritis.

      Patients and methods

      Clinical trial phase I- II, randomized , multicenter , with three treatment arms and 10
      patients for each group. The investigators compare the intraarticular injection of hialuronic
      acid against the administration of two different doses of mesenchymal stem cells with
      hialuronic acid according to the following scheme:

        1. Group A: intra-articular injection of hyaluronic acid (Hyalone®). Single dose.

        2. Group B: Low Dosage of MSCs . Intra-articular injection of 10 million autologous
           mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small
           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an
           intraarticular injection Hiaurónico Acid ( Hyalone®).

        3. Group C : High dose of MSCs. Intra-articular injection of 100 million autologous
           mesenchymal progenitor stem cells cultured ex - vivo ( cell suspension sterile small
           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an
           intraarticular injection Hiaurónico Acid (Hyalone®).

      The primary endpoint is safety and feasibility. The investigators registered the occurrence
      of complications and / or adverse effects during the study.

      In addition the investigators assess the response to intra-articular infusion of CMM
      analyzing the following parameters:

        -  Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since
           treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.

        -  Radiographic (baseline, 6 and 12 months since treatment): Femorotibial space.

        -  Radiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the
           number location of the lesions , cartilage thickness , signal intensity , subchondral
           bone alteration , volume and WORMS and dGEMRIC protocols.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological)
      of intra-articular administration of autologous mesenchymal stem cells (MSCs) in patients
      with knee osteoarthritis.

      Patients and methods

      Clinical trial phase I- II, randomized , multicenter , with three treatment arms and 10
      patients for each group. The investigators compare the intraarticular injection of hialuronic
      acid against the administration of two different doses of mesenchymal stem cells with
      hialuronic acid according to the following scheme:

        1. Group A: intra-articular injection of hyaluronic acid (Hyalone®). Single dose.

        2. Group B: Low Dosage of MSCs . Intra-articular injection of 10 million autologous
           mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small
           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an
           intraarticular injection Hiaurónico Acid ( Hyalone®).

        3. Group C : High dose of MSCs. Intra-articular injection of 100 million autologous
           mesenchymal progenitor stem cells cultured ex - vivo ( cell suspension sterile small
           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an
           intraarticular injection Hiaurónico Acid (Hyalone®).

      The autologous mesenchymal stem cells are obtained from the iliac crest and cultured ex vivo
      under local anesthesia and sedation.

      The primary endpoint is safety and feasibility. The investigators registered the occurrence
      of complications and / or adverse effects during the study.

      In addition the investigators assess the response to intra-articular infusion of CMM
      analyzing the following parameters:

        -  Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since
           treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.

        -  Radiographic (baseline, 6 and 12 months since treatment): Femorotibial space.

        -  Radiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the
           number location of the lesions , cartilage thickness , signal intensity , subchondral
           bone alteration , volume and WORMS and dGEMRIC protocols.

      All patients met the following inclusion and exclusion criteria:

      Inclusion Criteria:

        -  Males and females between 50 and 80 year old.

        -  Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American
           College of Rheumatology).

        -  Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS).

        -  Radiological Classification: Kellgren-Lawrence scale greater or equal to 2.

        -  Body mass index between 20 and 35 kg/m2.

        -  Ability to follow during the study period.

      Exclusion Criteria:

        -  Bilateral Osteoarthritis of the Knee requiring treatment in both knees.

        -  Previous diagnosis of polyarticular disease.

        -  Severe mechanical deformation.

        -  Arthroscopy during the previous 6 months.

        -  Intraarticular infiltration of hyaluronic acid in the last 6 months.

        -  Systemic autoimmune rheumatic disease.

        -  Poorly controlled diabetes mellitus.

        -  Blood dyscrasias.

        -  Immunosuppressive or anticoagulant treatments.

        -  Treatment with corticosteroids in the 3 months prior to inclusion in the study.

        -  NSAID therapy within 15 days prior to inclusion in the study.

        -  Patients with a history of allergy to penicillin or streptomycin.

        -  Allergy to hyaluronic acid or poultry proteins.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Visual analogue scale (VAS)</measure>
    <time_frame>prior to the initial dose on day 1</time_frame>
    <description>Baseline Visual analogue scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline value of knee injury and osteoarthritis outcome score (Koos).</measure>
    <time_frame>Prior to the intervention on day 1</time_frame>
    <description>Prior to the intervention on day 1 value of knee injury and osteoarthritis outcome score (Koos).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).</measure>
    <time_frame>Prior to the intervention on day 1</time_frame>
    <description>Prior to the intervention on day 1 Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline SF-36 value</measure>
    <time_frame>Prior to the intervention on day 1</time_frame>
    <description>Prior to the intervention on day 1 SF-36 value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline euroquol 5D value</measure>
    <time_frame>Prior to the intervention on day 1</time_frame>
    <description>Pretreatment euroquol 5D value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Lequesne index</measure>
    <time_frame>Prior to the intervention on day 1</time_frame>
    <description>Prior to the intervention on day 1 Lequesne index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline femorotibial distance</measure>
    <time_frame>Prior to the intervention</time_frame>
    <description>Prior to the intervention femoritibial distance on rosenberg x-ray view</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>Follow up</time_frame>
    <description>During the follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at on month</measure>
    <time_frame>1 month</time_frame>
    <description>Visual analogue scale (VAS) at on month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Visual analogue scale (VAS) at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Visual analogue scale (VAS) at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Visual analogue scale (VAS) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 3 month</measure>
    <time_frame>3 Months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 3 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 6 month</measure>
    <time_frame>6 months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 6 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 3 month</measure>
    <time_frame>3 months</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month</measure>
    <time_frame>6 months</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-36 value at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>SF-36 value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF 36 value at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>SF 36 value at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF 36 value at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>SF 36 value at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF 36 value at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>SF 36 value at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Euroquol 5D value at 1 month</measure>
    <time_frame>1 MOnth</time_frame>
    <description>Euroquol 5D value at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Euroquol 5D value at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Euroquol 5D value at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Euroquol 5D value at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Euroquol 5D value at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Euroquol 5D value at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Euroquol 5D value at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lequesne index at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Lequesne index at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lequesne index at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Lequesne index at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lequesne index at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Lequesne index at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lequesne index at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Lequesne index at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Femorotibial distance at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Femorotibial distance at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Femorotibial distance at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Femorotibial distance at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline MRI WORMS protocol</measure>
    <time_frame>Prior to the intervention</time_frame>
    <description>Prior to the intervention MRI WORMS protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI WORMS protocol score at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>MRI WORMS protocol score at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI WORMS protocol score at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>MRI WORMS protocol score at 12 months</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Hialuronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intraarticular injection of Hyaluronic acid (Hyal One)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic acid and MSC 10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic acid AND MSC 100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic acid</intervention_name>
    <description>Single intraarticular injection of Hyaluronic acid (Hyal One)</description>
    <arm_group_label>Hialuronic acid</arm_group_label>
    <arm_group_label>Hyaluronic acid and MSC 10</arm_group_label>
    <arm_group_label>Hyaluronic acid AND MSC 100</arm_group_label>
    <other_name>HyalOne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10 million Bone marrow mesenchimal stem cells</intervention_name>
    <description>10 million of Bone marrow mesenchimal stem cells</description>
    <arm_group_label>Hyaluronic acid and MSC 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>100 million Bone marrow mesenchimal stem cells</intervention_name>
    <description>100 million of Bone marrow mesenchimal stem cells</description>
    <arm_group_label>Hyaluronic acid AND MSC 100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between 50 and 80 year old.

          -  Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American
             College of Rheumatology).

          -  Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS).

          -  Radiological Classification: Kellgren-Lawrence scale greater or equal to 2.

          -  Body mass index between 20 and 35 kg/m2.

          -  Ability to follow during the study period.

        Exclusion Criteria:

          -  Bilateral Osteoarthritis of the Knee requiring treatment in both knees.

          -  Previous diagnosis of polyarticular disease.

          -  Severe mechanical deformation.

          -  Arthroscopy during the previous 6 months.

          -  Intraarticular infiltration of hyaluronic acid in the last 6 months.

          -  Systemic autoimmune rheumatic disease.

          -  Poorly controlled diabetes mellitus.

          -  Blood dyscrasias.

          -  Immunosuppressive or anticoagulant treatments.

          -  Treatment with corticosteroids in the 3 months prior to inclusion in the study.

          -  NSAID therapy within 15 days prior to inclusion in the study.

          -  Patients with a history of allergy to penicillin or streptomycin.

          -  Allergy to hyaluronic acid or poultry proteins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Lamo-Espinosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Prosper, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Blanco, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Traumatology department. Complejo Hospitalario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla y León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic and traumatology department. Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cun.es/actualidad/noticias/celulas-madre-osea-artrosis-rodilla</url>
    <description>University clinic of navarre trial information</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Mesenchimal stem cell</keyword>
  <keyword>Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

